Drug-filled particles could diagnose and treat cancer
Tiny particles filled with a drug could be a new tool for treating cancer in the future, claim researchers in Sweden.
A new study published in Particle & Particle Systems Characterization shows how such nanoparticles can be combined to secure the effective delivery of cancer drugs to tumour cells, and how they can be given properties to make them visible in MR scanners.
The team, which consisted of scientists from Karolinska Institutet (KI), the Royal Institute of Technology (KTH) in Stockholm, and Chalmers University of Technology in Gothenburg, developed so-called theranostic nanoparticles by combining therapy and diagnostics in a nanomaterial.
‘For this study, we produced theranostic nanoparticles able to make pinpoint deliveries of drug payloads to breast cancer cells,’ said Prof Eva Malmström of the School of Chemical Science and Engineering at KTH. ‘They are also detectable in an MR scanner and can therefore be used diagnostically. The building blocks that we use are biodegradable and show no signs of toxicity.’
The new study is said to have resulted in a method of making such theranostic nanoparticles that spontaneously form themselves out of tailored macromolecules.
The balance between hydrophilic and hydrophobic components are important to the successful outcome of this process, the latter being what makes it possible for the particles to be filled with the drug.
A relatively high concentration of the naturally occurring isotope fluorine-19 (19F) makes the particles show up clearly in high-resolution MR tomograms, and by tracking the theranostic nanoparticles through the body, researchers can learn about how the drug is taken up by the tumour and how efficacious the treatment is.
The researchers filled the nanoparticles with the chemotherapeutic doxorubicin, which is used to treat cancer of the bladder, lungs, ovaries, and breast.
They showed through experiments on cultivated cells that the particles, while harmless in themselves, are effective at killing cancer cells when loaded with the drug.
The next step is to develop the system to target brain tumours, pancreatic cancer and drug-resistant breast cancer tumours, which are currently difficult to treat effectively with chemotherapy.
‘Adding targeting groups to the surface or by changing the size of or adding ionic groups to our nanoparticles will make it possible to increase the selective uptake of these particles in tumours,’ said Dr Andreas Nyström, associate Professor in nanomedicine at the Swedish Medical Nanoscience Center, part of Karolinska Institutet’s Department of Neuroscience.
It is hoped that this research will eventually lead to tailored chemotherapy treatments that specifically seek out tumour cells. In that the drug, which is toxic to the body, can be delivered more precisely to the tumour and the treatment can be made much more effective with greatly reduced side-effects.
The abstract can be read here.